Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Asset Writedowns and Impairment (2018 - 2024)

Historic Asset Writedowns and Impairment for Dna X (SONM) over the last 7 years, with Q2 2025 value amounting to $1.1 million.

  • Dna X's Asset Writedowns and Impairment fell 6630.4% to $1.1 million in Q2 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 3512.42%. This contributed to the annual value of $6.5 million for FY2024, which is N/A changed from last year.
  • Per Dna X's latest filing, its Asset Writedowns and Impairment stood at $1.1 million for Q2 2025, which was down 6630.4% from $3.3 million recorded in Q4 2024.
  • Over the past 5 years, Dna X's Asset Writedowns and Impairment peaked at $3.3 million during Q4 2024, and registered a low of $2000.0 during Q1 2022.
  • Over the past 4 years, Dna X's median Asset Writedowns and Impairment value was $909000.0 (recorded in 2021), while the average stood at $1.3 million.
  • As far as peak fluctuations go, Dna X's Asset Writedowns and Impairment soared by 20813.56% in 2021, and later plummeted by 9967.0% in 2022.
  • Quarter analysis of 4 years shows Dna X's Asset Writedowns and Impairment stood at $909000.0 in 2021, then tumbled by 99.67% to $3000.0 in 2022, then surged by 108800.0% to $3.3 million in 2024, then crashed by 66.82% to $1.1 million in 2025.
  • Its Asset Writedowns and Impairment stands at $1.1 million for Q2 2025, versus $3.3 million for Q4 2024 and $3.2 million for Q2 2024.